1 CHPI 1080 copy.png
Waiting for new medicines in Canada, Europe, and the United States: Study finds Americans get better and faster access to innovative drugs
April 11, 2024 10:30 ET | Canadian Health Policy Institute Inc.
Americans get better and faster access to innovative medicines compared to Europeans and Canadians.
1 CHPI 1080 copy.png
Access to new medicines in Canada, Europe, and the United States: Study finds less availability and longer waits for Canadian patients
April 11, 2024 10:00 ET | Canadian Health Policy Institute Inc.
A recent study published by the Canadian Health Policy Institute examined the availability and wait times for access to new drugs.
US Gastroenterologis
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
April 05, 2024 09:17 ET | Spherix Global Insights
EXTON, PA, April 05, 2024 (GLOBE NEWSWIRE) -- As the first treatment to gain FDA approval for metabolic dysfunction-associated steatohepatitis (MASH), Madrigal Pharmaceuticals’ Rezdiffra...
PS phothi
IR-MED’s PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries
April 05, 2024 09:00 ET | IR-Med, Inc.
Marks major milestone prior to launch in U.S. marketPressureSafe™ scanner and disposable pack both listed with FDAPressureSafe™ can support early detection of pressure injuries, potentially setting a...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages InMode Ltd. Investors with Losses in Excess of $100k to Secure Counsel Before Important Deadline in Securities Class Action – INMD
April 02, 2024 15:42 ET | The Rosen Law Firm PA
NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of InMode Ltd. (NASDAQ: INMD) between June 4, 2021 and...
NurExone logo2.png
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update
April 02, 2024 08:31 ET | NurExone Biologic Inc
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A LEADING LAW FIRM, Encourages InMode Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INMD
March 28, 2024 11:28 ET | The Rosen Law Firm PA
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of InMode Ltd. (NASDAQ: INMD) between June 4, 2021 and...
enteralogo.png
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months
March 26, 2024 08:30 ET | Entera Bio Ltd.
JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides, announced today that The American...
UAA.png
Congress Passes Bills Making Major Investments in Alzheimer’s
March 23, 2024 10:15 ET | UsAgainstAlzheimer's
Congress passes major investments in the fight against Alzheimer’s.
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages InMode Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INMD
March 22, 2024 18:39 ET | The Rosen Law Firm PA
NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of InMode Ltd. (NASDAQ: INMD) between June 4, 2021 and...